Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
General Practice Department, Zhongshan Hospital, Fudan University, Shanghai, China.
Clin Lung Cancer. 2019 Sep;20(5):e584-e591. doi: 10.1016/j.cllc.2019.05.012. Epub 2019 May 29.
Tumor spread through air spaces (STAS) is a newly recognized invasion pattern in non-small-cell lung cancer (NSCLC). However, the clinical application value of STAS in NSCLC remains to be clarified. We aimed to comprehensively explore the potential role of STAS as a prognostic indicator in NSCLC.
A systematic search was performed in PubMed, Embase, Cochrane Library, and Web of Science until April 15, 2018. A quantitative meta-analysis was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
A total of 3231 patients from 8 studies were included. STAS was observed in 1204 cases (37.3%). A significant association was found between STAS and poor progression-free survival (PFS) (hazard ratio [HR], 1.789; P < .001) and overall survival (OS; HR, 1.488; P < .001). STAS was also an independent prognostic factor for PFS (HR, 1.632; P < .001) and OS (HR, 1.475; P < .001) without obvious heterogeneity. Subgroup analyses and meta-regression showed histology type, tumor, node, metastases (TNM) stage, publication year, sample size, region, and quality score did not alter prognostic value of STAS. Tumor STAS was associated with male sex (P < .001), history of smoking (P < .001), tumor budding (P = .038), vascular invasion (P < .001), lymphatic invasion (P < .001), pleural invasion (P < .001), T stage (P < .001), N stage (P < .001), and TNM stage (P < .001). The publication bias was observed. After adjustment using a nonparametric "trim-and-fill" method, corrected HRs had no significant change.
Tumor STAS is associated with clinicopathologically aggressive features and could be exploited as a novel prognostic predictor in NSCLC.
肿瘤通过气腔播散(STAS)是一种在非小细胞肺癌(NSCLC)中被新识别的侵袭模式。然而,STAS 在 NSCLC 中的临床应用价值仍有待阐明。我们旨在全面探讨 STAS 作为 NSCLC 预后指标的潜在作用。
我们在 PubMed、Embase、Cochrane 图书馆和 Web of Science 进行了系统检索,检索时间截至 2018 年 4 月 15 日。我们根据系统评价和荟萃分析的首选报告项目进行了定量荟萃分析。
共纳入 8 项研究的 3231 例患者。在 1204 例(37.3%)中观察到 STAS。STAS 与无进展生存期(PFS)(风险比 [HR],1.789;P<0.001)和总生存期(OS)(HR,1.488;P<0.001)显著相关。STAS 也是 PFS(HR,1.632;P<0.001)和 OS(HR,1.475;P<0.001)的独立预后因素,且无明显异质性。亚组分析和元回归显示,组织学类型、肿瘤、淋巴结、转移(TNM)分期、发表年份、样本量、地区和质量评分并未改变 STAS 的预后价值。肿瘤 STAS 与男性(P<0.001)、吸烟史(P<0.001)、肿瘤芽生(P=0.038)、血管侵犯(P<0.001)、淋巴血管侵犯(P<0.001)、胸膜侵犯(P<0.001)、T 分期(P<0.001)、N 分期(P<0.001)和 TNM 分期(P<0.001)有关。存在发表偏倚。使用非参数“修剪和填充”方法进行调整后,校正后的 HR 没有显著变化。
肿瘤 STAS 与临床病理侵袭特征相关,可作为 NSCLC 的一种新的预后预测因子。